BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series
4 affiliations
- 1Department of Medical Oncology, Toranomon Hospital
- 2Clinical Genetics Center, Toranomon Hospital
- 3Department of Urology, Toranomon Hospital
- 4Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Abstract
Background Prostate cancer with BRCA2 mutations has shown sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. However, acquired resistance remains a clinical concern. One potential mechanism of resistance is the emergence of reversion mutations that restore the function of BRCA2. Although this mechanism has been observed in other tumor types, only a limited number of clinical reports have described this phenomenon in prostate cancer. This case series highlights three patients in whom BRCA2 reversion mutations were detected following disease progression on olaparib. Case presentation We present three male patients diagnosed with metastatic castration-resistant prostate cancer, each carrying a germline BRCA2 mutation. All patients initially responded to olaparib, with a reduction in prostate-specific antigen levels and radiographic disease control. However, after approximately one year of treatment, each patient developed disease progression. Circulating tumor DNA analysis using a commercial liquid biopsy platform was performed after progression. In all cases, additional BRCA2 mutations were detected, including multiple variants predicted to restore the disrupted open reading frame of the BRCA2 gene. These findings were consistent with reversion mutations potentially restoring BRCA2 protein function and thereby conferring resistance to the PARP inhibitor. One patient additionally developed neuroendocrine differentiation during disease progression, highlighting the complexity of resistance evolution. Conclusions This case series provides clinical evidence that BRCA2 reversion mutations may underlie acquired resistance to olaparib in prostate cancer. These observations support the utility of liquid biopsy for detecting molecular mechanisms of resistance and suggest that reversion mutations may serve as a biomarker of treatment failure. Understanding such resistance mechanisms is essential for optimizing treatment sequencing and developing novel therapeutic strategies in BRCA2-mutated prostate cancer.
Related
- Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens
- Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis.
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- Generic context-dependence governs clonal emergence of ciprofloxacin resistance mutations
- SMARCA4 MUTATIONS PROMOTE CHEMOTHERAPY RESISTANCE IN T-ACUTE LYMPHOBLASTIC LEUKEMIA THROUGH ALTERED CHROMATIN REMODELING AT AP1-ASSOCIATED REGULATORY REGIONS
BibTeX
@article{takemura2026brca2,
title = {{BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series}},
author = {Kohji Takemura and Ayumi Abe and Kazushige Sakaguchi and Shinji Urakami and Masami Arai and Yuji Miura},
journal = {Hereditary Cancer in Clinical Practice},
year = {2026},
month = jul,
doi = {10.1186/s13053-026-00346-x},
url = {https://doi.org/10.1186/s13053-026-00346-x},
note = {CC BY},
}
RIS
TY - JOUR
TI - BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series
AU - Kohji Takemura
AU - Ayumi Abe
AU - Kazushige Sakaguchi
AU - Shinji Urakami
AU - Masami Arai
AU - Yuji Miura
PY - 2026
DA - 2026/07/01
JO - Hereditary Cancer in Clinical Practice
DO - 10.1186/s13053-026-00346-x
UR - https://doi.org/10.1186/s13053-026-00346-x
AB - Background Prostate cancer with BRCA2 mutations has shown sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. However, acquired resistance remains a clinical concern. One potential mechanism of resistance is the emergence of reversion mutations that restore the function of BRCA2. Although this mechanism has been observed in other tumor types, only a limited number of clinical reports have described this phenomenon in prostate cancer. This case series highlights three patients in whom BRCA2 reversion mutations were detected following disease progression on olaparib. Case presentation We present three male patients diagnosed with metastatic castration-resistant prostate cancer, each carrying a germline BRCA2 mutation. All patients initially responded to olaparib, with a reduction in prostate-specific antigen levels and radiographic disease control. However, after approximately one year of treatment, each patient developed disease progression. Circulating tumor DNA analysis using a commercial liquid biopsy platform was performed after progression. In all cases, additional BRCA2 mutations were detected, including multiple variants predicted to restore the disrupted open reading frame of the BRCA2 gene. These findings were consistent with reversion mutations potentially restoring BRCA2 protein function and thereby conferring resistance to the PARP inhibitor. One patient additionally developed neuroendocrine differentiation during disease progression, highlighting the complexity of resistance evolution. Conclusions This case series provides clinical evidence that BRCA2 reversion mutations may underlie acquired resistance to olaparib in prostate cancer. These observations support the utility of liquid biopsy for detecting molecular mechanisms of resistance and suggest that reversion mutations may serve as a biomarker of treatment failure. Understanding such resistance mechanisms is essential for optimizing treatment sequencing and developing novel therapeutic strategies in BRCA2-mutated prostate cancer.
SN - 1897-4287
ER -